Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calcitonin intranasal - Unigene

Drug Profile

Calcitonin intranasal - Unigene

Alternative Names: Fortical Intranasal; Nasal calcitonin - Unigene; Recombinant salmon calcitonin intranasal; Salcatonin intranasal - Unigene; sCT nasal

Latest Information Update: 31 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unigene Laboratories
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 11 Mar 2013 The US FDA Advisory Committe concludes that the benefits of calcitonin products do not outweigh the risks, and should not continue to be broadly marketed
  • 07 Jun 2011 Unigene terminates its involvement in Unigene Biotechnology (the China Joint Venture) and recovers all intellectual property rights granted under the agreement with Shijiazhuang Pharmaceutical Group
  • 03 Apr 2008 Phase-III clinical trials in Postmenopausal osteoporosis (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top